BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Myasthenia gravis clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for myasthenia gravis: 74 (38 sponsors; 7 newly posted in the last 180 days, 1 stopped in the last 180 days; 4 new-entrant sponsors). Momentum score 22.3, rank 21 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 8, Phase 2 17, Phase 3 29, Phase 4 3, N/A 16.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
argenx ARGX12P3 5, NA 4, P4 1, P2 211
UCB Biopharma SRL6P3 5, P4 101
Alexion Pharmaceuticals, Inc.8P3 4, NA 3, P4 101
Janssen Research & Development, LLC3P3 300
Novartis Pharmaceuticals NVS3P3 2, P2 101
Cartesian Therapeutics RNAC3P2 2, P3 101
Amgen AMGN2P2 1, P3 100
Dianthus Therapeutics DNTH2P3 1, P2 110
Immunovant Sciences GmbH IMVT1P3 100
Kyverna Therapeutics KYTX1P3 100
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1P3 100
Regeneron Pharmaceuticals REGN1P3 100
RemeGen Co., Ltd.1P3 101
Shanghai Jiaolian Drug Research and Development Co., Ltd1P3 101
Vor Biopharma VOR1P3 101
AstraZeneca AZN3NA 300
BioSensics2NA 200
Kite, A Gilead Company2P1 200
TG Therapeutics, Inc. TGTX2P2 1, P1 111
Aurinia Pharmaceuticals Inc. AUPH1P2 100
Biogen BIIB new entrant1P2 110
Cabaletta Bio CABA1P2 100
Candid Therapeutics1P1 100
Changchun GeneScience Pharmaceutical Co., Ltd. new entrant1P2 110
COUR Pharmaceutical Development Company, Inc.1P2 100

New-entrant sponsors: Biogen, Changchun GeneScience Pharmaceutical Co., Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2NMD Pharma A/SNCT06414954 Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia GravisMyasthenia Gravis; Myasthenia Gravis, MuSKrecruiting84
2026-12-15 est.P3Alexion Pharmaceuticals, Inc.NCT06607627 PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia GravisGeneralized Myasthenia Gravis; gMGrecruiting12
2026-12-30 est.P2/P3Shanghai Jiaolian Drug Research and Development Co., LtdNCT06447597 A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.Generalized Myasthenia Gravisrecruiting104
2026-12-31 est.P3RemeGen Co., Ltd.NCT07249632 A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)Myasthenia Gravis, Ocularrecruiting120

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-05P2/P3UCB Biopharma SRLNCT06149559 A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisGeneralized Myasthenia Graviscompleted14
2026-07-31P3UCB Biopharma SRLNCT04225871 Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisGeneralized Myasthenia Graviscompleted200
2026-07-15 est.P3Alexion Pharmaceuticals, Inc.NCT05644561 Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia GravisGeneralized Myasthenia Gravis; gMGactive not recruiting12
2026-06 est.P1/P2COUR Pharmaceutical Development Company, Inc.NCT06106672 Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia GravisMyasthenia Gravis; Generalized Myasthenia; AChR Myasthenia Gravis; MuSK MGactive not recruiting54

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "myasthenia gravis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.